Teleflex (NYSE:TFX) Issues Quarterly Earnings Results

Teleflex (NYSE:TFX) announced its quarterly earnings data on Thursday. The medical technology company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48, FiscalAI reports. The company had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.73 EPS. Teleflex updated its FY 2026 guidance to 6.900-7.200 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Second-quarter results exceeded expectations, with pro forma adjusted constant-currency revenue growth of 4.7% and adjusted EPS of $1.76, supported by strong vascular and surgical performance.
• Teleflex lowered its 2026 revenue-growth outlook to 3.5%-4.5% from 4.5%-5.5%, primarily because integration of the Vascular Intervention acquisition is taking longer than expected and is now expected to continue through the second half of the year.
• The company raised 2026 adjusted EPS guidance to $6.90-$7.20 from $6.25-$6.55, reflecting share repurchases, lower projected interest expense, and a reduced tax-rate outlook, while maintaining an adjusted operating-margin outlook of approximately 19%.
• Teleflex closed the OEM divestiture for approximately $1.5 billion in proceeds and used much of the after-tax proceeds to repay $700 million of debt; it also plans to begin an additional $250 million accelerated share repurchase and remains committed to $1 billion of buybacks and $800 million of debt reduction.
• Innovation milestones included FDA approval of EZPLAZ freeze-dried plasma and continued progress for the Freesolve resorbable magnesium scaffold, including early completion of BIOMAG-II enrollment and commencement of the U.S. pivotal BIOMAG-III trial.

Teleflex Stock Up 2.1%

Shares of NYSE:TFX opened at $139.61 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.55 and a debt-to-equity ratio of 0.82. Teleflex has a 52-week low of $100.18 and a 52-week high of $145.00. The stock’s fifty day simple moving average is $131.61 and its 200-day simple moving average is $122.46. The company has a market capitalization of $6.18 billion, a P/E ratio of -6.12, a P/E/G ratio of 1.02 and a beta of 0.81.

Teleflex Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Friday, August 14th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s payout ratio is -5.96%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. grew its holdings in shares of Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Teleflex in the fourth quarter valued at $45,000. Danske Bank A S acquired a new position in Teleflex in the third quarter valued at $54,000. State of Wyoming acquired a new position in Teleflex in the second quarter valued at $111,000. Finally, EverSource Wealth Advisors LLC lifted its position in Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after buying an additional 521 shares during the period. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex reported second-quarter adjusted earnings of $1.76 per share, well above the $1.28 analyst consensus, while revenue of $570.3 million exceeded estimates of $559.6 million. Revenue from continuing operations rose 28.9% year over year, or 4.7% on a pro forma constant-currency basis. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: The company raised or reaffirmed a favorable FY 2026 outlook, projecting adjusted EPS of $6.90 to $7.20, above the $6.70 consensus estimate. Full-year revenue guidance of approximately $2.3 billion was broadly in line with expectations. Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
• Positive Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, payable September 30 to shareholders of record August 14. The dividend provides an annualized payout of approximately $1.36 per share and a yield near 1%.
• Neutral Sentiment: The earnings comparison is complicated by a sharp decline in reported profitability: GAAP diluted EPS from continuing operations was $0.96, versus $1.54 a year earlier, while adjusted EPS fell from $3.73 to $1.76. The company also reported a negative net margin, suggesting that investors remain focused on the quality and sustainability of earnings growth. Teleflex Second Quarter Financial Results

Analyst Ratings Changes

A number of brokerages have recently issued reports on TFX. Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $135.00 to $155.00 in a research report on Friday, May 8th. Wells Fargo & Company upped their target price on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Piper Sandler raised Teleflex from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $140.00 to $160.00 in a report on Monday, June 8th. UBS Group began coverage on Teleflex in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $145.00 price target on the stock. Finally, Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $148.90.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.